バイオサイトジェンはB-NDGマウスより構築したCDXモデルでさまざまな薬効研究を行っています。これらのモデルは肺がん、直腸がん、結腸がん、乳がん、脾臓癌、膀胱がん、グリオブラストーマ、肝臓がん、各白血病及びリンパ腫細胞株、ヒトの実腫瘍及び血液腫瘍細胞株などが含めています。弊社はお客様のご依頼に応じて、皮下、in situ、または転移性腫瘍モデルを確立し、薬力学(PD)サービスを提供します。


カタログCDXモデル


Cell linesTumor typeCell linesTumor type
Human solid tumor cell linesNCI-H1975Lung carcinoma, non-small cellZR-75-1Breast ductal carcinoma
HCC827Lung adenocarcinomaMDA-MB-231Breast adenocarcinoma
NCI-H520Lung carcinomaDU4475Breast carcinoma, triple negative
A549Lung carcinomaMCF7Mammary gland, breast adenocarcinoma
NCI-H1781Lung carcinoma bronchoalveolar5637Bladder grade II carcinoma
HCT-8Colorectal Ileocecal adenocarcinomaA431Epidermoid carcinoma
HCT-116Colon carcinomaLN229Glioblastoma
Colo205Colorectal adenocarcinomaMiapaca-2Pancreatic carcinoma
Human blood tumor cell lines

 

DaudiLymphoma,NAMALWABurkitt’s lymphoma
KG-1Leukemia, acute myelogenous (AML)Kasumi-1Leukemia, acute myeloblastic (AML)
RajiLymphoma, Burkitt’sSU-DHL-1Large cell lymphoma, Diffuse histiocytic lymphoma
K562Leukemia (CML)MV4-11Peripheral blood biphenotypic B myelomonocytic leukemia

ルシフェラーゼマーカー細胞株のCDXモデル

No.Cell nameCancer type
B-HCL-013B-luciferase-GFP Raji Cell LineLymphoma, Burkitt’s
B-MCL-001B-luciferase-GFP HT-29 Cell LineColorectal adenocarcinoma
B-MCL-002B-luciferase-GFP H-1975 Cell LineLung carcinoma, non-small cell
B-HCL-014B-luciferase K562 Cell LineLeukemia (CML)
B-HCL-015B-luciferase MIA PaCa-2 Cell LinePancreatic carcinoma
B-HCL-010B-luciferase U-87MG cell line Glioblastoma

CDXマウスモデルの腫瘍成長曲線

事例1:HT-29-GFP Luciferase(ルシフェラーゼ)細胞を移植後第6/16/28日のNOD-scidマウスの生体イメージング

A) The mouse on the left was injected with 5 x 106 cells. The mouse on the right was injected with 5 x 105 (B) Signal intensity and tumor size graph.


事例2:4T1-Luciferase(ルシフェラーゼ)細胞の移植の後、7/14/21日のNOD-scidマウスの生体イメージング


(A) The mouse on the left was injected with 5 x 106 cells; the mice on right was injected with 5 x 105 cells. (B) Signal intensity and tumor size graph.



事例3:ヒトB細胞リンパ腫のCDXモデル

Raji cells (5×10⁶) were injected into B-NDG, NOD-scid and BALB/C nude mice. (A) Kaplan-Merier survival curves. (B) Relative body weight change. (C) Percentage of human cells in mouse peripheral blood quantified by q-PCR. (D) Liver tumor nodules. (E) Immunohistochemical staining of livers and spleens.

B-NDGモデルによる薬物効果の評価

研究事例1

Raji-Fluc cells (5 x 10⁵) were injected into B-NDG mice. Antibody X was administered on specified days. (A) Representative in vivo imaging recorded at different time points to monitor tumor progression. (B) Tumor load (as indicated by luciferase activity) kinetic curves post antibody treatment. Early dosing on day 3 in addition to day 10 resulted in robust tumor growth inhibition. In contrast, a single dose at day 10 had little effect.


研究事例2

Humanized B-NDG mice engrafted with human CD34+ HSC were intravenously injected with 5 x 10⁵ Raji-Fluc cells. Five days after Raji-Fluc cells implantation, mice were treated with anti-human PD-1 antibody. (A) Images of tumor load as indicated by luciferase activity. Tumor growth was dramatically inhibited by the human PD-1 antibody at day 7. RC=Raji-Fluc + Control. PDH=Antibody X + Humanized Mice. Naive B-NDG=Untreated Group.

Back to top